Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 17/20 | 0.97 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.70 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.70 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.70 |
| ▸ | TP53 | P04637 | 2/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.64 |
| ▸ | TSHR | P16473 | 2/20 | 0.64 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.64 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.64 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.64 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.64 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.64 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7536460 | 0.98 | SIGMAR1 (1.00) | SIGMAR1SLC6A4SLC6A3SLC6A2TP53 | |
| SCHEMBL7217896 | 0.85 | SIGMAR1 (0.97) | SIGMAR1SLC6A4SLC6A3SLC6A2TP53 | |
| SCHEMBL791606 | 0.84 | SIGMAR1 (0.97) | SIGMAR1SLC6A4SLC6A3SLC6A2TP53 | |
| SCHEMBL7332913 | 0.83 | SIGMAR1 (1.00) | SIGMAR1SLC6A4SLC6A3SLC6A2TP53 | |
| SCHEMBL12648455 | 0.78 | SIGMAR1 (1.00) | SIGMAR1TP53CYP1A2CYP2D6TSHR | |
| SCHEMBL3856961 | 0.78 | HRH3 (0.68) | SIGMAR1SLC6A3CYP1A2CYP3A4 | |
| SCHEMBL7427824 | 0.77 | SIGMAR1 (0.74) | SIGMAR1SLC6A4SLC6A3SLC6A2TP53 | |
| SCHEMBL678162 | 0.77 | SIGMAR1 (1.00) | SIGMAR1TP53CYP1A2CYP2D6TSHR | |
| SCHEMBL7218599 | 0.76 | SIGMAR1 (0.59) | SIGMAR1SLC6A4SLC6A3SLC6A2TP53 | |
| SCHEMBL791946 | 0.76 | SIGMAR1 (0.58) | SIGMAR1SLC6A4SLC6A3SLC6A2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030138432-A1 | Selective cellular targeting: multifunctional delivery vehicles, multifunctional prodrugs, use as antineoplastic drugs | DRUG INNOVATION & DESIGN, INC. | 2003-07-24 | — | — | US | disclosed |
| US-6517811-B2 | Diagnosing a mammal for presence of a tumor by administering compounds such as 125-I-(2-piperidinylaminoethyl)-4-iodobenzamide which have an affinity for cell surface sigma receptors | RESEARCH CORPORATION TECHNOLOGIES, INC. | 2003-02-11 | — | — | US | disclosed |
| EP-1255567-A1 | SELECTIVE CELLULAR TARGETING: MULTIFUNCTIONAL DELIVERY VEHICLES | Drug Innovation & Design, Inc. (US) | 2002-11-13 | — | — | EP | disclosed |
| US-6447748-B1 | Benzamide compounds for cancer imaging and therapy | RESEARCH CORPORATION TECHNOLOGIES, INC. | 2002-09-10 | — | — | US | disclosed |
| US-20010006619-A1 | Compounds for cancer imaging and therapy | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 2001-07-05 | — | — | US | disclosed |
| WO-2001036003-A2 | SELECTIVE CELLULAR TARGETING: MULTIFUNCTIONAL DELIVERY VEHICLES | DRUG INNOVATION & DESIGN, INC. (US) | 2001-05-25 | — | — | WO | disclosed |
| US-6015543-A | DIAGNOSIS OF TUMORS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 2000-01-18 | — | — | US | disclosed |
| US-5993777-A | Benzamide compounds for cancer imaging and therapy | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1999-11-30 | — | — | US | disclosed |
| US-5919934-A | BISAMINOTHIOL AND AMINO COMPOUNDS WITH APPENDED PHARMACOPHORES, METAL COMPLEXES OF THESE COMPOUNDS; | THE GEORGE WASHINGTON UNIVERSITY (US) | 1999-07-06 | — | — | US | disclosed |
| US-5911970-A | ANTITUMOR AGENTS AND ANTICARCINOGENIC AGENTS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1999-06-15 | — | — | US | disclosed |
| EP-0821594-A1 | COMPOUNDS FOR CANCER IMAGING AND THERAPY | JOHN, Christy S. (US) | 1998-02-04 | — | — | EP | disclosed |
| WO-1996032968-A1 | COMPOUNDS FOR CANCER IMAGING AND THERAPY | JOHN CHRISTY S (US) | 1996-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010006619-A1 | Compounds for cancer imaging and therapy | SIGMAR1, TMEM97, ADRB3 | SIGMAR1 1/4885SLC6A4 99/4885SLC6A3 133/4885 |
| US-20030138432-A1 | Selective cellular targeting: multifunctional delivery vehicles, multifunctional prodrugs, use as antineoplastic drugs | PAICS, ABCB1, ABCG2 | SIGMAR1 1368/4885SLC6A4 1177/4885SLC6A3 963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.